You must login before you can run this tool.
Tuberculosis Model Incorporating Treatment, Vaccination, and Antibiotic Resistance
Run though an interactive application to learn more about the consequences of antibiotic resistant pathogens through the lens of Tuberculosis.
Category
Published on
Abstract
Tuberculosis (TB) is a bacterial infection of the lungs that presents with a persistent cough sometimes including blood, fever, and sudden weight loss. Currently, TB is the most deadly infectious disease in the world claiming the lives of about 1.4 million people every year (WHO: TB, 2020). TB is also known to acquire resistance to the antibiotics used to treat it, and as a strain becomes resistant to more antibiotics, the likelihood that treatment will be successful dramatically decreases. The purpose of this model is to demonstrate the consequences of the development of antibiotic resistance in deadly diseases by simulating the spread of TB through a population.
References
Abu-Raddad, L. J., Sabatelli, L., Achterberg, J. T., Sugimoto, J. D., Longini, I. M., Dye, C., & Halloran, M. E. (2009). Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proceedings of the National Academy of Sciences, 106(33), 13980-13985. doi:10.1073/pnas.0901720106
[Inspiring Paper]
Cruz, A. T., & Starke, J. R. (2018). Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens. Pediatrics, 141(2). doi:10.1542/peds.2017-2838
[Presented the rates at which patients stop their therapy]
Executive Summary. (2020). World Drug Report World Drug Report 2020, 10-24. doi:10.18356/ceb25f4c-en
[Reported the prevalence of MDR-TB]
Information Sheet Observed Rate of Vaccine Reactions: Bacille Calmette-Guérin (BCG) Vaccine. (april 2012). World Health Organization Global Vaccine Safety, Immunization, Vaccines and Biologicals.
[Reported the fatality data for BCG Vaccinations]
Lotte A, ten Dam HG, Henderson R (1988). Second IUATLD study on complications induced by intradermal BCG vaccination. Bulletin of the International Union Against Tuberculosis and Lung Disease, 63(2):47–59. (Sub-citation of Information Sheet, 2012)
Talbot E, Perkins MD, Silva SFM, Frothingham R (1997). Disseminated Bacille Calmette-Guérin disease after vaccination: case report and review. Clinical Infectious Diseases, 24:1139–46. (Sub-citation of Information Sheet, 2012)
Institute of Medicine (US). Facing the Reality of Drug-Resistant Tuberculosis in India: Challenges and Potential Solutions: Summary of a Joint Workshop by the Institute of Medicine, the Indian National Science Academy, and the Indian Council of Medical Research. Washington (DC): National Academies Press (US); 2012. 4, Preventing Transmission of Drug-Resistant TB. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100392/
[Reported on the fitness of Resistant TB Strains]
Ma, Y., Horsburgh, C. R., White, L. F., & Jenkins, H. E. (2018). Quantifying TB transmission: A systematic review of reproduction number and serial interval estimates for tuberculosis. Epidemiology and Infection, 146(12), 1478-1494. doi:10.1017/s0950268818001760
[Reported R0 values for TB]
Ndjeka, N., Schnippel, K., Master, I., Meintjes, G., Maartens, G., Romero, R., . . . Conradie, F. (2018). High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. European Respiratory Journal, 52(6), 1801528. doi:10.1183/13993003.01528-2018
[Reported the efficacy of antibiotic treatment against TB]
Nguipdop-Djomo, P., Heldal, E., Rodrigues, L. C., Abubakar, I., & Mangtani, P. (2016). Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: A retrospective population-based cohort study. The Lancet Infectious Diseases, 16(2), 219-226. doi:10.1016/s1473-3099(15)00400-4
[Reported on the efficacy of the BCG Vaccination]
Vynnycky, Emilia; (1996) An investigation of the transmission dynamics of M. tuberculosis. PhD thesis, London School of Hygiene & Tropical Medicine. DOI: https://doi.org/10.17037/PUBS.00682231
[Reported on the uninhibited prevalence of TB]
World Health Organization (WHO): consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
[Reported on the lengths of MDR-TB Treatment]
World Health Organization (WHO): Tuberculosis (TB). (2020, October 14). Retrieved December 18, 2020, from https://www.who.int/news-room/fact-sheets/detail/tuberculosis
[Provided general background information about TB]
Cite this work
Researchers should cite this work as follows: